| name | endo-dhea-generalized-use-against |
| description | Recommends against routine use of dehydroepiandrosterone in women because indications are inadequate and evidence of efficacy and long-term safety is lacking. Triggers include a clinician considering DHEA supplementation for general well‑being, adrenal insufficiency, or other non‑specific indications. |
Recommend against generalized DHEA use in women
STEP 1 — Gather Information
Collect the reason for considering DHEA (e.g., fatigue, low libido, general well‑being), any specific medical condition (adrenal insufficiency, hypopituitarism, surgical menopause), baseline DHEAS/DHEA if available, current therapies, and signs of androgen excess.
STEP 2 — Rule In / Rule Out
Is the indication a generalized, non‑specific goal (e.g., general well‑being, aging, fatigue without a defined endocrine deficiency)? If yes → recommend against DHEA (proceed to STEP 4). If the indication is a specific condition (adrenal insufficiency, hypopituitarism, etc.) → proceed to STEP 3.
STEP 3 — Classify or Stratify
For specific indications, classify as “limited evidence”: data on efficacy and long‑term safety are insufficient; routine use is not supported, but a short‑term, monitored trial may be considered only after shared decision‑making.
STEP 4 — Decide
Recommend against routine DHEA use. If a specific indication is present and the patient insists, discuss the lack of evidence, obtain informed consent, consider a short‑term (e.g., 3‑month) trial with clinical monitoring for efficacy and androgenic side effects, and plan to discontinue if no benefit.
Clinical Guardrails / Mimics / Pitfalls
Do not prescribe DHEA for general well‑being or aging‑related symptoms; avoid long‑term (>6 months) use without clear benefit; do not substitute DHEA for glucocorticoid replacement in adrenal insufficiency; monitor for virilizing effects (acne, hirsutism, voice changes) if used; do not rely on DHEA to treat infertility, cognitive decline, cardiovascular risk, or bone health.
Concrete Clinical Example
A 48‑year‑old woman with stable glucocorticoid‑replaced primary adrenal insufficiency reports persistent fatigue and low mood. Her clinician considers DHEA 25 mg daily. Following the guideline, the clinician discusses the inadequate evidence, decides against routine DHEA, optimizes glucocorticoid dosing, screens for depression, and initiates aerobic exercise instead.
Source: Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, American Society for Reproductive Medicine, American College of Obstetricians and Gynecologists, European Society of Endocrinology, International Menopause Society, 2014, DOI:10.1210/jc.2014-2260
